Brief: Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
29/02/2024 13:37
Feb 29 (Reuters) - Imunon Inc IMNN.O :
* INDEPENDENT LAB CONFIRMS IMMUNOGENICITY AND PROTECTION
WITH
IMUNON’S IMNN-101 IN A LIVE VIRUS CHALLENGE AGAINST SARS-COV-2
VARIANT XBB.1.5
Source text for Eikon: ID:nGNX9cVZMt
Further company coverage: IMNN.O
((Reuters.Briefs@thomsonreuters.com;))